Skip to main content
Che Colpitts PhD
 Che Colpitts
Assistant Professor
Contact Info
Botterell Hall, Room 714

Academic Experience

  • 2017 – 2019: Research Associate, Division of Infection and Immunity, University College London, UK
  • 2014 – 2017: Postdoctoral Researcher, Institute of Viral and Liver Disease, University of Strasbourg, France
  • 2009 – 2014: PhD in Virology, University of Alberta, Canada
  • 2007 – 2009: MSc in Biochemistry, University of Regina, Canada
  • 2003 – 2007: BSc in Biochemistry, University of Regina, Canada

Research Interests

We focus on the biology of positive-sense RNA viruses, a group that includes established and emerging pathogens posing a serious threat to human health, such as Flaviviridae (e.g. hepatitis C virus (HCV), dengue virus and West Nile virus) and Coronaviridae (e.g. SARS and MERS coronaviruses). Positive-sense RNA viruses rearrange host intracellular membranes to form membranous viral replication organelles (ROs) in the cytoplasm of infected cells. We characterise virus-host interactions seeking to understand how positive-sense RNA viruses form ROs, and to characterise how cells sense and respond to these membrane rearrangements. We aim to identify perspectives for novel antiviral strategies broadly active against emerging and currently untreatable positive-sense RNA viruses.

Please see for more details

Selected Publications

  1. Colpitts CC*, Ridewood S, Schneiderman B, Warne J, Tabata K, Ng CF, Bartenschlager R, Selwood D and Towers GJ*. (2020) Hepatitis C virus exploits cyclophilin A to evade PKR. eLife 9:e52237 (*co-corresponding author)
  2. Eller C, Heydmann L, Colpitts CC, El Saghire H, Piccioni F, Jühling F, Mazjoub K, Pons C, Bach C, Lucifora J, Lupberger J, Nassal M, Cowley GS, Fujiwara N, Hsieh SY, Hoshida Y, Felli E, Pessaux P, Sureau C, Schuster C, Root DE, Verrier ER and Baumert TF. (2020) A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor. Nat. Comm. 11:2707
  3. Colpitts CC, Tsai P-L and Zeisel MB. (2020) Hepatitis C virus entry: An intriguingly complex and highly regulated process. Int. J. Mol. Sci. 21: pii:E20190
  4. Olbrich A, Wardemann J, Böhm S, Rother K, Colpitts CC, Wrensch F, Baumert TF, Berg T and Beckert J. (2019) Repertoire and neutralizing activity of antibodies against E2 peptide in patients with spontaneous resolution of hepatitis CJ. Infect. Dis. doi: 10.1093/infdis/jiz274.
  5. Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Pessaux P, Zeisel MB and Baumert TF (2018) Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escapeGut doi: 10.1136/gutjnl-2016-312577
  6. Eller C, Heydmann L, Colpitts CC, Verrier ER, Schuster C and Baumert TF (2018) The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D virusesCell. Mol. Life Sci.71:3895-3905
  7. Behrendt P, Perin P, Menzel N, Banda D, Pfaender S, Alves MP, Thiel V, Meulemann P, Colpitts CC, Schang LM, Vondran FWR, Kusuma A, Manns MP, Steinmann E and Pietschmann T (2017) Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entryAntiviral Res. 147:19-28 
  8. Colpitts CC and Baumert TF (2017) SMAD about hepatitis C virus cell entry and liver diseaseGastroenterology 152:21-23 
  9. Verrier ER#, Colpitts CC#, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset FL, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB and Baumert TF (2016) Solute carrier NTCP regulates innate antiviral immune responses targeting hepatitis C virus infection of hepatocytesCell Reports 17:1357-1368 (#equal contribution)
  10. Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F, Durantel D, Abou-Jaoudé G, López Ledesma MM, Felmlee DJ, Soumillon M, Croonenborghs T, Pochet N, Nassal M, Schuster C, Brino L, Sureau C, Zeisel MB and Baumert TF (2016) A targeted functional RNAi screen uncovers glypican 5 as an entry factor for hepatitis B and D virusesHepatology 63:35-48 
  11. Colpitts CC, Lupberger J and Baumert TF (2016) Multifaceted role of E-cadherin in hepatitis C virus infection and pathogenesisProc. Natl. Acad. Sci. USA 113:7298-300 
  12. Colpitts CC and Baumert TF (2016) Addressing the challenges of hepatitis C virus resistance and treatment failureViruses doi: 10 3390/v8080226 
  13. Fauvelle C, Colpitts CC, Keck Z, Pierce BG, Foung SKH and Baumert TF (2016) Hepatitis C virus B cell vaccines inducing protective neutralizing antibodiesExpert Rev. Vaccines doi:10 1080/14760584 2016 1194759 
  14. Tawar RG, Colpitts CC, Timm J, Fehm T, Roggendorf M, Meisel H, Meyer N, Habersetzer F, Cosset FL, Berg T, Zeisel MB and Baumert TF (2015) Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing propertiesHepatology 62:726-36 
  15. Kusuma A, Romero-Brey I, Berger C, Colpitts CC, Boldanova T, Engelmann M, Todt D, Perin PM, Behrendt P, Vondran FW, Xu S, Goffinet C, Schang LM, Heim MH, Bartenschlager R, Pietschmann T and Steinmann E (2015) Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication via blockage of membranous web formationHepatology 62:702-14 
  16. Colpitts CC and Baumert TF (2015) A new HCV cell culture model for the next clinical challengesNat. Rev. Gastro. Hepatol. 12:611-13 
  17. Colpitts CC, El-Saghire H, Pochet N, Schuster C and Baumert TF (2015) High-throughput approaches to unravel hepatitis C virus-host interactionsVirus Res. 218: 18-24
  18. Colpitts CC, Verrier ER and Baumert TF (2015) Targeting viral entry for treatment of hepatitis B and C virus infectionsACS Infect. Dis. 1:420-427 
  19. Colpitts CC, Lupberger J, Doerig C and Baumert TF (2015) Host cell kinases and the hepatitis C virus life cycleBiochim. Biophys. Acta Proteins Proteom. 1854:1657-62 
  20. Colpitts CC, Zeisel MB and Baumert TF (2015) When one receptor closes, another opens: Claudins and the hepatitis C virus E1 glycoproteinHepatology 62:991-3 
  21. Colpitts CC and Schang LM (2014) A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycansJ. Virol. 88:7806-17 
  22. Kusuma A, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, Brown RJP, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pietschmann T and Steinmann E (2014) Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cellsGut 63:1137-49
  23. Colpitts CC, Ustinov AV, Epand RF, Epand RM, Korshun VA and Schang LM (2013) 5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza, hepatitis C and other enveloped virusesJ. Virol. 87(7): 3640-54
  24. Ciesek S, von Hahn T, Colpitts CC, Schang LM, Friesland M, Steinmann J, Manns MP, Ott M, Wedermeyer H, Meuleman P, Pietschmann T and Steinmann E (2011) The green tea polyphenol epigallocatechin-3-gallate (EGCG) inhibits hepatitis C virus (HCV) entryHepatology 54:1947-55
  25. St Vincent MR, Colpitts CC, Ustinov AV, Muqadas M, Joyce MA, Barsby NL, Epand RF, Epand RM, Khramyshev SA, Valueva OA, Korshun VA, Tyrrell DLJ and Schang LM (2010Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped virusesProc. Natl. Acad. Sci. USA 107:17339-44